File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1038/onc.2011.272
- Scopus: eid_2-s2.0-84856949774
- PMID: 21743496
- WOS: WOS:000300222100006
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma
Title | Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Authors | |||||||||||||
Keywords | anti-angiogenic fibulin-2 methylation nasopharyngeal carcinoma tumor suppressor VEGF | ||||||||||||
Issue Date | 2012 | ||||||||||||
Publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/onc | ||||||||||||
Citation | Oncogene, 2012, v. 31 n. 6, p. 728-738 How to Cite? | ||||||||||||
Abstract | Fibulin-2 (FBLN2) has been identified as a candidate tumor-suppressor gene in nasopharyngeal carcinoma (NPC). Originally identified through a chromosome 3 NotI genomic microarray screen, it shows frequent deletion or methylation in NPC. FBLN2 is located on chromosome 3p25.1 and is associated with tumor development through its important interactions with the extracellular matrix (ECM) proteins. FBLN2 encodes two isoforms. The short isoform (FBLN2S) is expressed abundantly in normal tissues, but is dramatically downregulated in NPC, while the long isoform (FBLN2L) is either not detectable or is expressed only at low levels in both normal and tumor tissues. Reintroduction of this FBLN2S inhibited cell proliferation, migration, invasion and angiogenesis in vitro. Furthermore, in vivo studies in nude mice show its expression is associated with tumor and angiogenesis suppression. FBLN2-associated angiogenesis occurs via concomitant downregulation of vascular endothelial growth factor and matrix metalloproteinase 2. This study provides compelling evidence that FBLN2S has an important tumor-suppressive and anti-angiogenic role in NPC. © 2012 Macmillan Publishers Limited All rights reserved. | ||||||||||||
Persistent Identifier | http://hdl.handle.net/10722/134395 | ||||||||||||
ISSN | 2023 Impact Factor: 6.9 2023 SCImago Journal Rankings: 2.334 | ||||||||||||
ISI Accession Number ID |
Funding Information: This work was supported by University Grants Council Area of Excellence grant AoE/M-06/08 to MLL and the Swedish Cancer Society, the Swedish Research Council, the Swedish Institute, and Karolinska Institute to ERZ. | ||||||||||||
References | |||||||||||||
Grants |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Law, EWL | en_HK |
dc.contributor.author | Cheung, AKL | en_HK |
dc.contributor.author | Kashuba, VI | en_HK |
dc.contributor.author | Pavlova, TV | en_HK |
dc.contributor.author | Zabarovsky, ER | en_HK |
dc.contributor.author | Lung, HL | en_HK |
dc.contributor.author | Cheng, Y | en_HK |
dc.contributor.author | Chua, D | en_HK |
dc.contributor.author | LaiWan Kwong, D | en_HK |
dc.contributor.author | Tsao, SW | en_HK |
dc.contributor.author | Sasaki, T | en_HK |
dc.contributor.author | Stanbridge, EJ | en_HK |
dc.contributor.author | Lung, ML | en_HK |
dc.date.accessioned | 2011-06-17T09:19:16Z | - |
dc.date.available | 2011-06-17T09:19:16Z | - |
dc.date.issued | 2012 | en_HK |
dc.identifier.citation | Oncogene, 2012, v. 31 n. 6, p. 728-738 | en_HK |
dc.identifier.issn | 0950-9232 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/134395 | - |
dc.description.abstract | Fibulin-2 (FBLN2) has been identified as a candidate tumor-suppressor gene in nasopharyngeal carcinoma (NPC). Originally identified through a chromosome 3 NotI genomic microarray screen, it shows frequent deletion or methylation in NPC. FBLN2 is located on chromosome 3p25.1 and is associated with tumor development through its important interactions with the extracellular matrix (ECM) proteins. FBLN2 encodes two isoforms. The short isoform (FBLN2S) is expressed abundantly in normal tissues, but is dramatically downregulated in NPC, while the long isoform (FBLN2L) is either not detectable or is expressed only at low levels in both normal and tumor tissues. Reintroduction of this FBLN2S inhibited cell proliferation, migration, invasion and angiogenesis in vitro. Furthermore, in vivo studies in nude mice show its expression is associated with tumor and angiogenesis suppression. FBLN2-associated angiogenesis occurs via concomitant downregulation of vascular endothelial growth factor and matrix metalloproteinase 2. This study provides compelling evidence that FBLN2S has an important tumor-suppressive and anti-angiogenic role in NPC. © 2012 Macmillan Publishers Limited All rights reserved. | en_HK |
dc.language | eng | en_US |
dc.publisher | Nature Publishing Group. The Journal's web site is located at http://www.nature.com/onc | en_HK |
dc.relation.ispartof | Oncogene | en_HK |
dc.subject | anti-angiogenic | en_HK |
dc.subject | fibulin-2 | en_HK |
dc.subject | methylation | en_HK |
dc.subject | nasopharyngeal carcinoma | en_HK |
dc.subject | tumor suppressor | en_HK |
dc.subject | VEGF | en_HK |
dc.title | Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0950-9232&volume=in press&spage=&epage=&date=2011&atitle=Anti-angiogenic+And+Tumor-suppressive+Roles+Of+Candidate+Tumor+Suppressor+Gene,+Fibulin-2,+In+Nasopharyngeal+Carcinoma | en_US |
dc.identifier.email | Cheung, AKL: arthurhk@hku.hk | en_HK |
dc.identifier.email | Lung, HL: hllung2@hku.hk | en_HK |
dc.identifier.email | Cheng, Y: yuecheng@hku.hk | en_HK |
dc.identifier.email | Chua, D: dttchua@hkucc.hku.hk | en_HK |
dc.identifier.email | LaiWan Kwong, D: dlwkwong@hku.hk | en_HK |
dc.identifier.email | Tsao, SW: gswtsao@hkucc.hku.hk | en_HK |
dc.identifier.email | Lung, ML: mlilung@hku.hk | en_HK |
dc.identifier.authority | Cheung, AKL=rp01769 | en_HK |
dc.identifier.authority | Lung, HL=rp00299 | en_HK |
dc.identifier.authority | Cheng, Y=rp01320 | en_HK |
dc.identifier.authority | Chua, D=rp00415 | en_HK |
dc.identifier.authority | LaiWan Kwong, D=rp00414 | en_HK |
dc.identifier.authority | Tsao, SW=rp00399 | en_HK |
dc.identifier.authority | Lung, ML=rp00300 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1038/onc.2011.272 | en_HK |
dc.identifier.pmid | 21743496 | en_HK |
dc.identifier.scopus | eid_2-s2.0-84856949774 | en_HK |
dc.identifier.hkuros | 185871 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-84856949774&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 31 | en_HK |
dc.identifier.issue | 6 | en_HK |
dc.identifier.spage | 728 | en_HK |
dc.identifier.epage | 738 | en_HK |
dc.identifier.eissn | 1476-5594 | - |
dc.identifier.isi | WOS:000300222100006 | - |
dc.publisher.place | United Kingdom | en_HK |
dc.relation.project | Centre for Nasopharyngeal Carcinoma Research | - |
dc.identifier.scopusauthorid | Law, EWL=36742183700 | en_HK |
dc.identifier.scopusauthorid | Cheung, AKL=8967932600 | en_HK |
dc.identifier.scopusauthorid | Kashuba, VI=34770221200 | en_HK |
dc.identifier.scopusauthorid | Pavlova, TV=35314397400 | en_HK |
dc.identifier.scopusauthorid | Zabarovsky, ER=7007009108 | en_HK |
dc.identifier.scopusauthorid | Lung, HL=6603819904 | en_HK |
dc.identifier.scopusauthorid | Cheng, Y=36131038300 | en_HK |
dc.identifier.scopusauthorid | Chua, D=7006773480 | en_HK |
dc.identifier.scopusauthorid | LaiWan Kwong, D=15744231600 | en_HK |
dc.identifier.scopusauthorid | Tsao, SW=7102813116 | en_HK |
dc.identifier.scopusauthorid | Sasaki, T=7407396809 | en_HK |
dc.identifier.scopusauthorid | Stanbridge, EJ=7103249410 | en_HK |
dc.identifier.scopusauthorid | Lung, ML=7006411788 | en_HK |
dc.identifier.citeulike | 9543910 | - |
dc.identifier.issnl | 0950-9232 | - |